Cognitive/neurodegenerative disorders drug pipelines

Abbvie

Duodopa Next Gen

Parkinson's disease

Phase III


Abbvie

Duodopa

Parkinson's disease

Approved


Acorda

SYN120

Parkinson's disease

Phase II


Acorda

Tozadenant

Parkinson's disease

Phase III


Acorda

CVT-301

Parkinson's disease

Phase III


Astellas

ASP4345

Schizophrenia, cognitive impairment

Phase I


Dainippon Sumitomo Pharma

DSP-3748

Cognitive impairment & schizophrenia

Phase I


Dainippon Sumitomo Pharma

Zonisamide

Parkinson's disease

Phase III


Pfizer

PF-05251749

Alzheimer's disease

Phase I


Roche

RG7314

Autism

Phase II


Roche

RG6100

Alzheimer's disease

Phase I


Teva

deutetrabenazine

Huntington's disease

Approval


Teva

Copaxone

Multiple sclerosis

Approval


Teva

Pridopidine

Huntington's disease

Phase II


Teva

Laquinimod

Multiple sclerosis (progressive), Huntington's disease & Multiple sclerosis (relapsing-remitting)

Phase II & III


Teva

deuldopa

Parkinson's disease

Phase I


Takeda

Rasagiline

Parkinson's disease

Monoamine oxidase B (MAO-B) inhibitor

Phase III


Takeda

AD-4833/TOMM40

Alzheimer's disease

Insulin sensitizer

Phase III


Takeda

glatiramer acetate

Multiple sclerosis

Immunomodulator

Approved


Sanofi

SAR228810

Alzheimer's disease

Anti-protofibrillar AB mAb

Phase I


Sanofi

GZ402668

Multiple sclerosis

anti-CD52 mAb

Phase I


Roche

Gantenerumab

Alzheimer's disease

monoclonal antibody

Phase III


Pfizer

PF-06751979

Alzheimer's disease

Phase I


Pfizer

PF-06648671

Alzheimer's disease

Phase I


Pfizer

PF-04958242

Alzheimer's disease

Phase I


Pfizer

PF-06649751

Parkinson's disease

Modulator of dopamine signaling

Phase II


Pfizer

PF-02545920

Huntington's disease

PDE10 inhibitor

Phase II


Otsuka

Lu AF20513

Alzheimer's disease

beta-amyloid vaccine

Phase I


Otsuka

dextromethorphan, quinidine

Parkinson's disease dyskinesia

NMDA receptor antagonist/Serotonin and Norepinephrine reuptake inhibitor/Sigma-1 receptor agonist/Neuronal nicotinic receptor antagonist

Phase II


Otsuka

idalopirdine

Alzheimer's disease

selective 5-HT6 receptor antagonist

Phase III


Novartis

CNP520

Alzheimer's disease

BACE inhibitor

Phase II


Novartis

CAD106

Alzheimer's disease

Beta­-amyloid ­protein therapy

Phase II


Novartis

ofatumumab

Multiple sclerosis (relapsing)

Anti­CD­20 monoclonal antibody

Phase II


Novartis

siponimod

Multiple sclerosis (secondary progressive)

Phase III


Novartis

fingolimod

Multiple sclerosis (pediatric)

Sphingosine-1-phosphate receptor modulator

Phase III


Merck

verubecestat

Alzheimer's disease

inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE)

Phase III


Eisai

E2027

Alzheimer's disease

Phase I


Eisai

E2609

Alzheimer's disease

BACE inhibitor

Phase II


Eisai

BAN2401

Alzheimer's disease

lgG1 monoclonal antibody

Phase II


Eisai

donepezil

Alzheimer's disease

inhibition of acetylcholinesterase

Approval


Biogen

BIIB054

Parkinson's disease

anti-α-synuclein

Phase I


Biogen

E2609

Alzheimer's disease

BACE1 inhibitor

Phase II


Biogen

BAN2401

Alzheimer's disease

amyloid-beta mAb

Phase II


Biogen

Ocrelizumab

Multiple sclerosis (primary progressive & relapsing)

monoclonal antibody targeting CD20-positive B cells

Phase III


Biogen

Aducanumab

Alzheimer's disease

amyloid-beta mAb

Phase III


AstraZeneca

Amaranth

Alzheimer's disease (early)

beta-secratase inhibitor

Phase III


AstraZeneca

AZD3241

Multiple system atrophy

myeloperoxidase inhibitor

Phase II


AstraZeneca

MEDI1814

Alzheimer's disease

amyloid beta mAb

Phase I


Amgen

AMG 520

Alzheimer's disease (prevention)

inhibitor of BACE

Phase II


Abbvie

ABT-957

Alzheimer's disease

Phase I


Abbvie

ABBV-672

Alzheimer's disease

Phase I


Roche

RG7935

Parkinson's disease

monoclonal antibody targeting alpha-synuclein

Phase I


Eli lilly

BACE - AZD3293

Alzheimer's disease

BACE inhibitor

Phase III


Eli lilly

D1 potentiator

dementia

Phase I


Eli lilly

BACE inhibitor

Alzheimer's disease

Phase I


Eli lilly

A ß antibody Fab PEG

Alzheimer's disease

Phase I


Eli lilly

N3pG-Aß

Alzheimer's disease

Monoclonal Antibody

Phase I


Shire

TH/GCH1

Parkinson's disease

Preclinical


Teva & Takeda

Rasagiline

Parkinson's disease

Norepinephrine uptake inhibitor

Phase II


Eisai

BAN2401

Alzheimer's disease

Phase II


GlaxoSmithKline

rilapladib

Alzheimer's disease

Lp-PLA2 inhibitor

Phase II


GlaxoSmithKline

rilapladib

Alzheimer's disease

Lp-PLA2 inhibitor

Phase II


Abbvie

ABT-126

Cognitive Impairment Associated with Schizophrenia

α-7 nicotinic acetylcholine receptor (α7-nAChR) allosteric modulator

Phase II


Teva Pharmaceutical Industries Ltd

Pridopidine

Huntington's Disease

Phase II


Teva Pharmaceutical Industries Ltd

Laquinimod

Multiple Sclerosis (Progressive forms), Huntington Disease

Immunomodulator

Phase II


Lilly

LY2062430 (solanezumab)

Alzheimer's disease

Phase III


Merck

MK-8931

Alzheimer's Disease

Phase II


TauRx Therapeutics

LMTX

Dementia

Tau Aggregation Inhibitor

Phase III


Roche

RG7412 crenezumab

Alzheimer's disease

Monoclonal antibody

Phase II